CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,259,123 | -26.9% | 45,753 | -9.9% | 0.00% | 0.0% |
| Q2 2023 | $1,722,389 | -4.5% | 50,763 | +1.2% | 0.00% | -33.3% |
| Q1 2023 | $1,804,469 | -20.3% | 50,152 | -1.3% | 0.00% | -25.0% |
| Q4 2022 | $2,265,404 | +60.3% | 50,828 | +1.1% | 0.00% | +100.0% |
| Q3 2022 | $1,413,000 | +2.2% | 50,283 | -1.9% | 0.00% | 0.0% |
| Q2 2022 | $1,382,000 | -21.2% | 51,270 | -0.4% | 0.00% | 0.0% |
| Q1 2022 | $1,753,000 | -19.6% | 51,457 | -8.9% | 0.00% | -33.3% |
| Q4 2021 | $2,181,000 | -28.7% | 56,457 | -0.4% | 0.00% | -25.0% |
| Q3 2021 | $3,060,000 | +69.2% | 56,683 | +4.8% | 0.00% | +100.0% |
| Q2 2021 | $1,808,000 | – | 54,079 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |